Enrico Bucci graduated summa cum laude in Biology in 1997 (University of Naples “Federico II”, Italy). After 2 years in Germany he earned a PhD in Biochemistry and Molecular Biology in 2001. In 2001, he was also appointed full researcher by the Italian CNR. In 2006, he founded his first start-up, BioNucleon Srl, prized as the Best Young and Innovative Italian Company and dedicated to nucleic-acid based drugs. It was incubated by the Canavese Bioindustry Park, which subsequently appointed Enrico Bucci as its CSO. By the end of 2008, after honouring all commitments related to his previous role, Enrico Bucci moved as CSO to Biodigitalvalley Srl, his second start-up, dedicated to bioinformatics. In January 2013, he was appointed CEO. In June 2016, he was appointed adjunct Professor of Biology and Director of the System Biology program of the Sbarro Health Research Organization in the College of Science and Technology of the Temple University (Philadelphia, US). In July 2016, Bucci founded Resis Srl, a company dedicated to Research Integrity. He co-authored about 80 papers on peer-reviewed international journals and was in charge for the scientific coordination of several projects, which often included both academic and industrial partners, in Italy and abroad.He is co-author of chapters in scientific books and he is author of a book dedicated to scientific fraud, published in September 2015. His work on detecting scientific fraud has been covered by several national and international magazines, including Nature (2013, 2015, 2016), and has been broadcasted by the Italian State TV (RAI). 